These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 15624094)

  • 1. Rosiglitazone and lipid metabolism.
    Ferrannini E
    Diabetologia; 2005 Jan; 48(1):6-7. PubMed ID: 15624094
    [No Abstract]   [Full Text] [Related]  

  • 2. Preventing the progression of diabetes mellitus.
    Reamy BV
    Am Fam Physician; 2005 Feb; 71(3):425. PubMed ID: 15712615
    [No Abstract]   [Full Text] [Related]  

  • 3. Nuclear peroxisome proliferator-activated receptors and thiazolidinediones.
    Grinberg A; Park KW
    Int Anesthesiol Clin; 2005; 43(2):1-21. PubMed ID: 15795559
    [No Abstract]   [Full Text] [Related]  

  • 4. The metabolic syndrome: relationship between insulin sensitivity and the role of peroxisome proliferator-activated receptors (PPARs) in saccharide and lipid metabolism.
    Yahia RB; Lichnovská R; Brychta T
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2005 Dec; 149(2):237-41. PubMed ID: 16601762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Healing the diabetic heart: modulation of cardiometabolic syndrome through peroxisome proliferator activated receptors (PPARs).
    Huang TH; Roufogalis BD
    Curr Mol Pharmacol; 2012 Jun; 5(2):241-7. PubMed ID: 22122453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tissue-specific effects of rosiglitazone and exercise in the treatment of lipid-induced insulin resistance.
    Lessard SJ; Rivas DA; Chen ZP; Bonen A; Febbraio MA; Reeder DW; Kemp BE; Yaspelkis BB; Hawley JA
    Diabetes; 2007 Jul; 56(7):1856-64. PubMed ID: 17440174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypoglycemic action of thiazolidinediones/peroxisome proliferator-activated receptor gamma by inhibition of the c-Jun NH2-terminal kinase pathway.
    Díaz-Delfín J; Morales M; Caelles C
    Diabetes; 2007 Jul; 56(7):1865-71. PubMed ID: 17416798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diabetes as a negative risk factor for abdominal aortic aneurysm - does the disease aetiology or the treatment provide the mechanism of protection?
    Torsney E; Pirianov G; Cockerill GW
    Curr Vasc Pharmacol; 2013 May; 11(3):293-8. PubMed ID: 22724482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct attenuation of plasminogen activator inhibitor type-1 expression in human adipose tissue by thiazolidinediones.
    Zirlik A; Leugers A; Lohrmann J; Ernst S; Sobel BE; Bode C; Nordt TK
    Thromb Haemost; 2004 Apr; 91(4):674-82. PubMed ID: 15045127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pioglitazone: beyond glucose control.
    de Pablos-Velasco P
    Expert Rev Cardiovasc Ther; 2010 Aug; 8(8):1057-67. PubMed ID: 20670183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin resistance and PPAR insulin sensitizers.
    Bhatia V; Viswanathan P
    Curr Opin Investig Drugs; 2006 Oct; 7(10):891-7. PubMed ID: 17086933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular effects of insulin sensitizers in diabetes.
    Jawa A; Fonseca V
    Curr Opin Investig Drugs; 2006 Sep; 7(9):806-14. PubMed ID: 17002258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Rosiglitazone(BRL-49653)].
    Yonezawa N; Oka Y
    Nihon Rinsho; 2001 Nov; 59(11):2195-9. PubMed ID: 11712407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [KRP-297, MCC-555].
    Yamanouchi T
    Nihon Rinsho; 2001 Nov; 59(11):2200-6. PubMed ID: 11712408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thiazolidinediones and PPAR orchestra as antidiabetic agents: From past to present.
    Yasmin S; Jayaprakash V
    Eur J Med Chem; 2017 Jan; 126():879-893. PubMed ID: 27988463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of rosiglitazone on peroxisome proliferator-activated receptor gamma gene expression in human adipose tissue is limited by antiretroviral drug-induced mitochondrial dysfunction.
    Mallon PW; Sedwell R; Rogers G; Nolan D; Unemori P; Hoy J; Samaras K; Kelleher A; Emery S; Cooper DA; Carr A;
    J Infect Dis; 2008 Dec; 198(12):1794-803. PubMed ID: 18954260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute and selective regulation of glyceroneogenesis and cytosolic phosphoenolpyruvate carboxykinase in adipose tissue by thiazolidinediones in type 2 diabetes.
    Cadoudal T; Blouin JM; Collinet M; Fouque F; Tan GD; Loizon E; Beale EG; Frayn KN; Karpe F; Vidal H; Benelli C; Forest C
    Diabetologia; 2007 Mar; 50(3):666-75. PubMed ID: 17242918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of rosiglitazone on fatty acid and triglyceride metabolism in type 2 diabetes.
    Tan GD; Fielding BA; Currie JM; Humphreys SM; Désage M; Frayn KN; Laville M; Vidal H; Karpe F
    Diabetologia; 2005 Jan; 48(1):83-95. PubMed ID: 15619071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of PPARg2 transcription factor in thiazolidinedione-induced insulin sensitization.
    Saraf N; Sharma PK; Mondal SC; Garg VK; Singh AK
    J Pharm Pharmacol; 2012 Feb; 64(2):161-71. PubMed ID: 22221092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [PPAR and diabetes].
    Terauchi Y; Kadowaki T
    Nihon Rinsho; 2005 Apr; 63(4):623-9. PubMed ID: 15828230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.